TW570803B - Influenza vaccine - Google Patents
Influenza vaccine Download PDFInfo
- Publication number
- TW570803B TW570803B TW087104913A TW87104913A TW570803B TW 570803 B TW570803 B TW 570803B TW 087104913 A TW087104913 A TW 087104913A TW 87104913 A TW87104913 A TW 87104913A TW 570803 B TW570803 B TW 570803B
- Authority
- TW
- Taiwan
- Prior art keywords
- surface antigen
- dna
- patent application
- influenza virus
- enzyme
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Description
570803 經濟部中央標準局員工消費合作社印黧 A7 B7 五、發明説明(!) 本發明係關於由在培養之動物細胞中繁殖之流行性感冒 病毒所製備的流行性感冒病毒表面抗原疫苗,與其表面抗 原蛋白質的製備方法。 流行性感冒病毒的大小約125毫微米,以核糖核酸爲核 心,並與核蛋白(mucleopr〇tein)結合,外層由具有雙層脂 質結構的病毒外鞘(envelope)所包覆。該外鞘的内層的主 要組成爲基質蛋白(matrix pr〇tein),而外層則主要含有來 的宿主的脂質成份。 所謂的"表面蛋白"是指出現在病毒表面棘(spike )的神 經胺酸甞酶(neuraminidase ; NA )與血球凝集素(1^11^881扒· inine ; HA) 〇 大部份市面上的去活化的流行性感冒疫苗爲所謂的”分 離疫苗(split vaccines ),,或次單元疫苗。 ’·分離疫苗”的製備是以適當濃度的清潔劑將整個流行性 感冒病毒溶解,接著除去清潔劑與大部份的脂質成份。 預防流行性感冒的·•次單元疫苗’’和’’分離疫苗”不同,它 不含所有的病毒蛋白,相反的,"次單元疫苗”含有較多 在接種時可謗導特定病毒的中和性(保護性)抗體產生的表 面蛋白。 目削市面上大部份的流行性感冒疫苗是由培養在難胚的 流行性感冒病毒所製備而得的。然而,爲所公認;以雞胚 培養產生的流行性感冒病疫苗,具有許多的缺點: 1·由於每個蛋的(微)生物品質不同,此種製備方法是比 較不可靠的。 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) (請先閱讀背面之注意事項再填寫本頁) 、11 sf 570803 經濟部中央標率局員工消費合作社印製 A7 B7 五、發明説明(2 ) 2. —旦需求增加,如:嚴重的流行病或大流行此種製備 法完全沒有變通性(flexibility ),因爲它的困難在於缺 乏大量可適用的蛋。 3. 此種製備法產生的疫苗對於那些對難或難蛋的蛋白質 會產生過敏的人,是禁忌使用的。 解決以上問題的方法也許可借助組織培養來繁衍流行性 感冒病毒,組織培養的方法具有許多優點: 1·組織培養細胞株可由無(微)生物污染的公認細胞庫系 統中取得,因此可大幅改善批次的一致性(batch_t〇_ batch consistency),並可獲得高品質的產物。 2·如果發生嚴重流行病或大流行時,較有可能提供足夠 的疫苗。 3.最後得到的流行性感冒病毒成份將更適用於其它的給 藥方式(口服,鼻用,吸入)。 4·從世界衛生組織(WHO )的觀點看來:此項技術將可延 長每年的疫苗組成更改(從二月中至三月中),增加疫 苗與循環中的病毒株的對抗力。 然而,以組織培養的方式取得流行性感冒病也有一項嚴 重的問題,那就是疫苗中可能出現同一宿主細胞株的遺傳 物質。 此問題如果沒有設法補救,則其潛藏的危機可能導致有 關當局基於安全考量拒絕此種流行性感冒疫苗申請上市的 請求。例如,美國食品藥物管理局要求針對人類使用的生 物科技產物每劑量不可含超過100微微克的宿主細胞 •------1T------. (請先閱讀背面之注意事項再填寫本頁) -5- 570803 經濟部中央標苹局員工消費合作社印製 A7 B7 五、發明説明(3 ) DNA 〇 因此,本發明提供一種製備流行性感冒疫苗表面抗原的 方法,其中該表面抗原是作爲疫苗使用,此種方法所製備 的疫苗是安全的,並不含無法接受量的有害遣傳物質,且 符合有關當局的要求。然而,在過去想要製備含宿主細胞 DNA低於1〇〇微微克/每劑量的流行性感冒疫苗一直被認 爲是奢望並令人驚I牙的。 所以’本發明係關於一流行性病毒表面抗原疫苗,該疫 苗是由經動物細胞繁殖而得的流行性感冒病毒製備而得 的,而且其中所含的宿主細胞DNA量等於或低於每劑量 25微微克。 在一特定具代表性實例中,本發明提供一種製備表面抗 原蛋白的方法,其中該表面抗原蛋白是用於製備含低量 DNA的流行性感冒疫苗,而這種流行性感冒病毒是由動 物細胞繁殖而得的。本方法含有下列步驟: a·以DNA分解酵素處理得自細胞培養物之含完整病毒之 液體,並且 b.添加陽離子清潔劑。 隨後,分離表面抗原蛋白質。 本發明的方法可應用於不同的流行性感冒病毒疫苗的生 產’典型的病毒包括人類流行性感冒,豬流行性感冒,馬 流行性感冒與禽流感。 本發明的動物細胞培養包括初級細胞,如:雞胚纖維織 母細胞(CEF)或永久細胞株,如馬汀黛比貓腎細胞 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) (請先閱讀背面之注意事項再填寫本頁) 、-口 ώψ. 570803 五、發明説明( (MDCK)中國倉鼠卵細胞(CH〇)與維羅(Ver〇)細胞。 DNA分解酵素分解具完整病毒體之培養液的過程可直接 在發酵槽中進行,最好是在細胞培養與病毒增殖的過程中 進行。 ,適合的DNA分解酵素爲DNA分解酶(DNase)(酵素編號 爲 121與五。3.1.22)與核酸酵素(1111(:16犯6)(酵素編號 爲 ’· EC 3.1.30 與EC 3.1.31)。 根據本發明,適合的陽離子性清潔劑最好爲含有下列化 學式的化合物 RN VR3 Λ x 一 其中 Ri,R2與 R 或及1與112 爲相同或不同,並且爲烷基或芳基, 與其所附接之氮原子結合形成5或6員飽 和雜環, 爲烷基或芳基, 經濟部中央標率局員工消費合作社印繁 或與&與其所附接之氮原子結合形成5或6員雜 環’其中不飽和位置在氮原子上, R4 爲烷基或芳基,且 X 爲陰離子。 陽離子清潔劑的實例包括鯨蠟基三甲基銨鹽,如:鯨蠟 基三甲基銨化溴(C.T.A.B.),與肉菫蔻基三甲基銨鹽。合 適的β潔劑還包括力玻菲叮(Hp〇fectine),力玻菲他命 經濟部中央標準局員工消費合作社印製 570803 A7 B7 五、發明説明(5 ) (lipofectamine ),DOTMA 0 這些陽離子清潔劑最好與非離子性清潔劑一起使用, 如:吐溫(Tween)。 凊潔劑處理後的表面抗原蛋白分離步驟可包括: 1 ·利用離心,或超高速離心將RNP顆粒(體)從表面抗原 蛋白中分離,且 2.利用清潔劑與特定樹脂(如:安伯萊特(Amberlite) XAD-4)間的厭水性相互作用,且/或超(透)過濾 (ultra(dia)filtration)將清潔劑從表面抗原蛋白中分離。 很令人驚訝地,本發明方法所得的產物,其中所含的動 物細胞DNA量是非常低的。DNA濃度可低至2 5毫微克/劑 量,並且很容量的可獲得低至10毫微克/劑量。 表面抗原蛋白可再經處理,以供製備流行性感冒疫苗使 用,這些處理包括:添加緩衝液(如:PBS ),且/或與其 它血清型的流行性感冒病毒一起混合。 表面抗原蛋白的濃度最好符合疫苗製備的要求。 實例1 A.病毒的增殖 1·在發酵槽中,將具有抗原型B/亞瑪加塔(Yamagata)之 流行性感冒病毒加入馬汀黛比貓腎(MDCK)細胞 (ATCC CCL34)中,於35。(:下培養2天,令病毒增殖。 2.然後,加入稀釋的氫氧化鈉以調高ρη値至8.0,並加 入班容(Benzon)核分解酶至終濃度爲每公升1〇〇〇單位 (1微克)。 -8- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公董) (讀先閱讀背面之注意事項再填寫本頁) ,ιτ 570803 A7 Β7 五、發明説明(6 ) 3. 在35°C下,作用4小時。 B · 病毒的分離 1·以濾孔大小爲0.5微公分的厚濾紙將培養液過濾,去除 細胞破片。 2·接著,使用可阻斷分子量300,000以上通過的過濾膜, 並藉由超高速離心將流行性感冒病毒濃縮及純化。 3·加入曱醛至最終濃度爲〇·〇15% (重量百分比;w/v) 後,再將庶糖加入至終濃度爲30% (w/v),然後將此混 合物置於2-8°C下攪拌72小時。 4. 接下來以磷酸緩衝食鹽液將濃縮的病毒稀釋五倍,並 置入含有阿美空(Amicon)塞絡芬(Cellufine)硫酸鹽的 親和性管柱中。以磷酸緩衝食鹽液清洗,去除雜質 後,以含有1.5莫耳氣化鈉濃度的磷酸缓衝食鹽液沖提 病毒,以可阻斷分子量30〇5〇〇〇以上的過濾膜,藉由超 而速離心將冲提液濃縮並且脱鹽(desalted )。 C.次單元的分雌 經濟部中央標準局員工消費合作社印製 (請先閱讀背面之注意事項再填寫本頁} -訂· 1·加入非離子性清潔劑吐溫_8〇至終濃度爲3〇〇微克/亳升 與溴化鯨基三甲基氨至終濃度爲750微克/毫升,接著 將此混合物置於4。(:下攪拌3小時後,藉由離心方式, 將RNP顆粒從表面抗原蛋白中分離出。 2·上層液與安伯萊特χΑΙ)·4 一起置於2_8。〇下隔夜攪拌以 去除β潔劑’以過濾方式將安伯菜特去除過濾液,緊 ^接著,以0.22微米的濾膜進行無菌過濾。 經過以上的處理,可使用有效的測試法來分析樣本中的 9- 570803 A7 B7 五、發明説明(7 ) 宿主細胞DNA的含量,該方法是使用32P-標定的貓DNA探 針,進行空位轉潰雜交(slot blot hybridisation )。 經過不同步驟處理後的DNA含量分析結果列於下列表格 中(在表格中,每個IVV劑量的DNA含量以每50微克HA 中含微微克(picogram )作爲代表。 表格 樣本 DNA含量 處理後 培養液48 hpi 19,000,000 A1 核分解酶處理後的培養液 370,000 A2 前過濾後的培養液 10,000 B1 超南速離心後的濃縮液 4350 B2 去活化並經親和性層析的滤液 4200 B4 經吐溫/C.T.A.B.處理與離心後的濾液 <25 C1 去除清潔劑後的濾液 <25 C2 實例2 在實例1中,病毒的增殖,純化,去活化與分解受到影 響。 經濟部中央標準局員工消費合作社印繁 (請先閱讀背面之注意事項再填寫本頁) 在病毒增殖的最後幾小時内(步驟A 2與A 3 ),以班容核 分解酶處理培養液,該核分解酶在增殖培養液的p Η値範 圍下作用(步驟A 1 ),可得到預期DNA去除的類似結果。 雖然核酸分解酶1需要較高的濃度,但是它在去除宿主 細胞DNA (步驟A1_A3 )是一樣有效的。其它的核酸内切酶 (endonuclease )也可得到類似的結果。 -10- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) 經濟部中央標準局員工消費合作社印繁 570803 A7 B7_ 五、發明説明(8 ) 實例3 除了以離心方式來去除細胞破片(步驟B 1 )外,其它的 步驟依照實例1或2。 實例4 除了以持續流動區帶離心機(continuous flow zonal centrifuge)如:Electro-Nucleonics (RK型),與庶糖梯度 如:以璘酸缓衝食鹽液配製,將培養液中的病毒濃縮與純 化(步驟B 2)外,其它的步驟依照實例1,2,或3。 實例5 除了以溴化歸基p比淀,溴化肉苴蔻基氨,氣化二異丁基 苯氧基乙氧基二甲基苯基氨(benzetonium chloride ),氯化 甲基二異丁基苯氧基乙氧基二曱基苯基氨,氣化十甲鑌 (decamethonium chloride ),或硬脂疏基二甲基苯基錄化溴 溶液來取代鯨蠟基三甲基銨化溴溶液,其它的步驟依照實 例1至4。可得到.預期宿主細胞DNA去除的類似結果。 實例6 除了親和性層析後加入蔗糖,共且加入甲酸至〇 〇5% (重量百分率濃度),作用最長爲120小時,其它步驟依照 實例1。 實例7 根據實例1,2,3,4與6的方法已成功的應用於製備 DNA含量低的B/哈賓(Harbin),B/巴拿馬(Panama),A/ 德州(Texas H1N1),A/臺灣(H1N1),A/約翰尼斯堡 (H3N2)與A/武漢(H3N2)等型的流行性病毒感冒疫苗。 -11 - 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) (請先閱讀背面之注意事項再填寫本頁)
Claims (1)
- 570803 第087104913號專利申請案 中文_請專利範圍替換本(92年10 ^J) A8 B8 C8 申請專利範園 1. -種流行性感冒病毒表面抗原疫苗,此疫苗是由流行性 感冒病毒㈣物細胞培養物上繁殖製得,其包括 驟: a·以DNA分解酵素處理得自么 、、、 目肩胞培養物的含完整病毒 之液體,且該DNA分解酵夸杨、联△丄從主 肝砰京係選自由酵素編號為E C 3I2UEC 3.K2uDNase與酵素編號為π 3· 1.3 0及EC 3.1.3 1之核酸酵素所組成之群; b.添加陽離子性清潔劑,並士 乎W 具王要係如下通式化合物所 組成: Ra X R4 其中 R!,R2與R3為相同或不同,且各為烷基或芳基, 或心㈣與其所附接之氮原子結合形成…員飽和雜 環,且R3為烷基或芳基, 或κ,r々r3與其所附接之氮原子結合形成5或6員雜 環’且不飽和處在氮原子上, R4為烷基或芳基,且 X為陰離子; c.分離表面抗原蛋白質,其係利用離心或超過滤法將 RNP顆粒(體)自表面抗原蛋白質中分出,接著利用 清潔劑與適當樹脂間的厭水性相互作用,及/或利用 超過濾法,將清潔劑自表面抗原蛋白質中分出; 本紙張尺度適用中國國家標準(CNS) A4規格(210 X 297公复) A BCD 570803 、申請專利範圍 3. 且其宿主細胞DNA含量等於或低於每劑量2 5微微克。 2.根據申請專利範圍第1項之流行性感冒病毒表面抗原疫 苗,其中宿主細胞DNA含量低於每劑量1 〇微微克。 一種在動物細胞培養物上繁殖流行性感冒病毒來製備表 面抗原蛋白質的方法,其包括下列步驟: a.以DNA分解酵素處理得自細胞培養物的含完整病毒 之液體,且該D N A分解酵素係選自由酵素編號為E c 3.1.21及EC 3.1.22之DNase與酵素編號為ec 3.1.30及EC 3.1.31之核酸酵素所組成之群;b. 添加陽離子性清潔劑,其主要係如下通式化合物所 組成: Ri\ Λ 其中Ri,R2與R3為相同或不同,且各為烷基或芳基,或 RAR2與其所附接之氮料結合形成5或6員飽和雜環, 且R3為烷基或芳、基, ,认’ MR3與其所附接之氮原子結合形成5或6員雜 環’且不飽和處在氮原子上, R4為烷基或芳基,且 X為陰離子; C.L=抗原蛋白質,其係利用離心或超過滤法將 ㈣顆粒(體)自表面抗原蛋白質中分出,接著利用 清潔劑與適當樹脂間的厭水性相互作用,及/或利用 -2 - I紙張尺度適财_^^s) Α4_·χ297公 570803 A8 B8 C8超過濾法,將清潔劑自表面抗原蛋白質中分出。 屯根據申請專利範圍第3項之方法,其中dna分解酵素的 處理係於流行性感冒病毒在細胞培養物上繁殖時進行。 5·根據巾請專利範m第3項的方法,丨中陽離子性清潔劑 主要包含鯨蠟基三甲基銨化溴。 6. 根據申請專利範圍第3項的方法,丨中陽離子性清潔劑 中補充了非離子性清潔劑。 7. 根據申請專利範圍第3項的方法,其中流行性感冒病毒 在動物細胞株上繁殖。 8. 根據申請專利範圍第3項的方法,其中流行性感冒病毒 在MDCK細胞上繁殖。 -3 -本紙張尺度適用中國國家標準(CNS) Α4規格(210 X 297公釐)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97201007 | 1997-04-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW570803B true TW570803B (en) | 2004-01-11 |
Family
ID=8228174
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW087104913A TW570803B (en) | 1997-04-09 | 1998-04-01 | Influenza vaccine |
Country Status (32)
Country | Link |
---|---|
US (1) | US5948410A (zh) |
EP (1) | EP0870508B1 (zh) |
JP (1) | JP5258127B2 (zh) |
KR (1) | KR100593235B1 (zh) |
CN (1) | CN1138564C (zh) |
AR (1) | AR011216A1 (zh) |
AT (1) | ATE197406T1 (zh) |
AU (1) | AU728939B2 (zh) |
BR (1) | BR9801015A (zh) |
CA (1) | CA2234208C (zh) |
CZ (1) | CZ297492B6 (zh) |
DE (2) | DE870508T1 (zh) |
DK (1) | DK0870508T3 (zh) |
DZ (1) | DZ2462A1 (zh) |
ES (1) | ES2129386T3 (zh) |
GR (2) | GR990300017T1 (zh) |
HK (1) | HK1010833A1 (zh) |
HR (1) | HRP980187B1 (zh) |
HU (1) | HUP9800802A3 (zh) |
ID (1) | ID20399A (zh) |
IL (1) | IL123961A (zh) |
NO (1) | NO323349B1 (zh) |
NZ (1) | NZ330131A (zh) |
PL (1) | PL187982B1 (zh) |
PT (1) | PT870508E (zh) |
RU (1) | RU2197264C2 (zh) |
SI (1) | SI0870508T1 (zh) |
SK (1) | SK282614B6 (zh) |
TR (1) | TR199800613A1 (zh) |
TW (1) | TW570803B (zh) |
UA (1) | UA42089C2 (zh) |
ZA (1) | ZA982915B (zh) |
Families Citing this family (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU764368B2 (en) * | 1999-09-24 | 2003-08-14 | Smithkline Beecham Biologicals (Sa) | Intranasal influenza virus vaccine |
GB9923176D0 (en) * | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
CN100415769C (zh) * | 2002-02-07 | 2008-09-03 | 中国科学院过程工程研究所 | 寡聚或多聚亚基蛋白质分离纯化的方法 |
MXPA04010603A (es) | 2002-04-30 | 2004-12-13 | Oncolytics Biotech Inc | Metodos mejorados de purificacion viral. |
US20060110406A1 (en) * | 2003-02-25 | 2006-05-25 | Medimmune Vaccines, Inc. | Refrigerator-temperature stable influenza vaccine compositions |
KR101251902B1 (ko) * | 2003-02-25 | 2013-04-08 | 메디뮨 엘엘씨 | 인플루엔자 백신 조성물의 제조 방법 |
US7270990B2 (en) * | 2003-06-20 | 2007-09-18 | Microbix Biosystems, Inc. | Virus production |
US8592197B2 (en) | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
US8506967B2 (en) | 2003-07-11 | 2013-08-13 | Novavax, Inc. | Functional influenza virus like particles (VLPs) |
US8992939B2 (en) | 2003-07-11 | 2015-03-31 | Novavax, Inc. | Highly efficient influenza matrix (M1) proteins |
US8080255B2 (en) | 2003-07-11 | 2011-12-20 | Novavax Inc. | Functional influenza virus like particles (VLPs) |
US20070207461A1 (en) | 2004-02-23 | 2007-09-06 | Crucell Holland B.V. | Virus Purification Methods |
CA2559371C (en) | 2004-03-09 | 2014-07-08 | Chiron Corporation | Influenza virus vaccines |
CA2890962A1 (en) | 2004-09-09 | 2006-03-16 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | Decreasing potential iatrogenic risks associated with influenza vaccines |
US7901921B2 (en) | 2004-10-22 | 2011-03-08 | Oncolytics Biotech Inc. | Viral purification methods |
CA2586690A1 (en) | 2004-11-03 | 2006-06-15 | Novartis Vaccines And Diagnostics, Inc. | Influenza vaccination |
ES2526170T3 (es) * | 2004-12-23 | 2015-01-07 | Medimmune, Llc | Línea celular MDCK no tumorigénica para propagar virus |
NZ561823A (en) | 2005-03-23 | 2010-04-30 | Glaxosmithkline Biolog Sa | Use of an influenza virus and an oil-in-water emulsion adjuvant to induce cd4 t-cell and/or improved b-memory cell response |
US8574595B2 (en) * | 2005-04-11 | 2013-11-05 | Crucell Holland B.V. | Virus purification using ultrafiltration |
NZ567817A (en) | 2005-11-01 | 2012-01-12 | Novartis Vaccines & Diagnostic | Cell-derived viral vaccines with low levels of residual cell DNA by beta-propiolactone treatment |
US11707520B2 (en) | 2005-11-03 | 2023-07-25 | Seqirus UK Limited | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
US20090304742A1 (en) | 2005-11-04 | 2009-12-10 | Novartis Vaccines And Diagnostics Srl | Influenza vaccines with reduced amount of emulsion adjuvant |
WO2007052061A2 (en) * | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics Srl | Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines |
DK2368572T3 (da) | 2005-11-04 | 2020-05-25 | Seqirus Uk Ltd | Adjuvansvacciner med ikke-virionantigener fremstillet fra influenza-virusser dyrket i cellekultur |
CN102727885A (zh) | 2005-11-04 | 2012-10-17 | 诺华疫苗和诊断有限公司 | 包含颗粒佐剂和免疫增强剂组合的流感疫苗 |
JP2009514839A (ja) | 2005-11-04 | 2009-04-09 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | サイトカイン誘導剤を含むアジュバントインフルエンザワクチン |
WO2007085969A2 (en) | 2006-01-27 | 2007-08-02 | Novartis Vaccines And Diagnostics Gmbh & Co Kg | Influenza vaccines containing hemagglutinin and matrix proteins |
JP2009534303A (ja) | 2006-03-24 | 2009-09-24 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー | 冷蔵しないインフルエンザワクチンの保存 |
JP2009532352A (ja) | 2006-03-31 | 2009-09-10 | ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション | ワクチンのための高力価組み換えインフルエンザ・ウィルス |
EP2043682B1 (en) | 2006-07-17 | 2014-04-02 | GlaxoSmithKline Biologicals S.A. | Influenza vaccine |
GB0614460D0 (en) * | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
CA3016948A1 (en) | 2006-09-11 | 2008-03-20 | Seqirus UK Limited | Making influenza virus vaccines without using eggs |
MX2009002741A (es) | 2006-09-15 | 2009-05-11 | Medimmune Llc | Lineas de celulas mdck que soportan el crecimiento viral para altos titulos y proceso de biorreactor que utiliza las mismas. |
NZ577405A (en) | 2006-12-06 | 2012-08-31 | Novartis Ag | Vaccines including antigen from four strains of influenza virus |
BRPI0808333B8 (pt) * | 2007-03-05 | 2021-05-25 | Om Pharma | extrato bacteriano para doenças respiratórias e processo para sua preparação |
WO2008112218A2 (en) | 2007-03-12 | 2008-09-18 | Antigen Express, Inc. | Li-rnai involved li suppression in cancer immunotherapy |
TW200908994A (en) | 2007-04-20 | 2009-03-01 | Glaxosmithkline Biolog Sa | Vaccine |
WO2008156778A2 (en) | 2007-06-18 | 2008-12-24 | Tokiko Watanabe | Influenza m2 protein mutant viruses as live influenza attenuated vaccines |
CA2692200A1 (en) | 2007-06-27 | 2008-12-31 | Novartis Ag | Low-additive influenza vaccines |
EP2772267B1 (en) * | 2007-08-27 | 2016-04-27 | Longhorn Vaccines and Diagnostics, LLC | Immunogenic compositions and methods |
GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
EP2889042A3 (en) | 2008-03-18 | 2015-10-14 | Novartis AG | Improvements in preparation of influenza virus vaccine antigens |
CA2738022A1 (en) | 2008-09-24 | 2010-04-01 | Medimmune, Llc | Methods for cultivating cells, propagating and purifying viruses |
CA2741961A1 (en) * | 2008-11-05 | 2010-05-14 | Glaxosmithkline Biologicals S.A. | Novel method |
EP2942062A1 (en) | 2009-02-10 | 2015-11-11 | Novartis AG | Influenza vaccine regimens for pandemic-associated strains |
US20120093860A1 (en) | 2009-02-10 | 2012-04-19 | Novartis Ag | Influenza vaccines with increased amounts of h3 antigen |
PL2396032T3 (pl) | 2009-02-10 | 2017-05-31 | Seqirus UK Limited | Szczepionki przeciw grypie o obniżonych zawartościach skwalenu |
USH2284H1 (en) | 2009-04-27 | 2013-09-03 | Novartis Ag | Vaccines for protecting against influenza |
EP2401384B1 (en) | 2009-05-21 | 2012-10-03 | Novartis AG | Reverse genetics using non-endogenous pol i promoters |
WO2010144797A2 (en) | 2009-06-12 | 2010-12-16 | Vaccine Technologies, Incorporated | Influenza vaccines with enhanced immunogenicity and uses thereof |
CA2767392C (en) | 2009-07-06 | 2017-03-14 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
US9907746B2 (en) | 2009-07-06 | 2018-03-06 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
AU2010277310B2 (en) | 2009-07-31 | 2015-01-15 | Seqirus UK Limited | Reverse genetics systems |
SG178904A1 (en) | 2009-09-10 | 2012-04-27 | Novartis Ag | Combination vaccines against respiratory tract diseases |
PL2491117T3 (pl) | 2009-10-20 | 2014-05-30 | Novartis Ag | Udoskonalone sposoby odzyskiwania wirusa wykorzystujące odwrotną genetykę |
US9109013B2 (en) | 2009-10-26 | 2015-08-18 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses with enhanced replication in vero cells |
US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
CN103025350A (zh) | 2010-05-21 | 2013-04-03 | 诺华有限公司 | 流感病毒的重配方法 |
PL2575873T3 (pl) | 2010-06-01 | 2016-06-30 | Novartis Ag | Zatężanie i liofilizacja antygenów szczepionkowych grypy |
CA2801149A1 (en) | 2010-06-01 | 2011-12-08 | Novartis Ag | Concentration of vaccine antigens without lyophilization |
CA2840079C (en) | 2010-07-06 | 2018-07-03 | Variation Biotechnologies Inc. | Compositions and methods for treating influenza |
CA2808965C (en) | 2010-08-20 | 2020-01-07 | Novartis Ag | Soluble needle arrays for delivery of influenza vaccines |
AU2012205315B2 (en) | 2011-01-13 | 2017-05-04 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
WO2012097346A1 (en) | 2011-01-13 | 2012-07-19 | Variation Biotechnologies, Inc. | Compositions and methods for treating viral infections |
CA2852857A1 (en) | 2011-10-20 | 2013-04-25 | Novartis Ag | Adjuvanted influenza b virus vaccines for pediatric priming |
US20140328876A1 (en) | 2011-11-18 | 2014-11-06 | Variation Biotechnologies Inc. | Synthetic derivatives of mpl and uses thereof |
EP2802353A4 (en) | 2012-01-12 | 2015-12-02 | Variation Biotechnologies Inc | COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS |
US20150079077A1 (en) | 2012-01-27 | 2015-03-19 | Variation Biotechnologies, Inc. | Methods and compositions for therapeutic agents |
ES2628301T3 (es) | 2012-03-02 | 2017-08-02 | Seqirus UK Limited | Recombinación de virus de gripe |
WO2013182498A1 (en) | 2012-06-04 | 2013-12-12 | Novartis Ag | Improved safety testing |
GB201218195D0 (en) | 2012-10-10 | 2012-11-21 | Istituto Zooprofilattico Sperimentale Delle Venezie | Composition |
MX2015006927A (es) | 2012-12-03 | 2016-02-05 | Novartis Ag | Redistribucion de virus de la influenza. |
CN111334530A (zh) | 2013-03-13 | 2020-06-26 | 诺华股份有限公司 | 乙型流感病毒重配 |
JP2016521282A (ja) | 2013-05-10 | 2016-07-21 | ノバルティス アーゲー | インフルエンザワクチンにおけるナルコレプシーのリスクの回避 |
DE202013005130U1 (de) | 2013-06-05 | 2013-09-10 | Novartis Ag | Influenza Virus Reassortierung |
DE202013005100U1 (de) | 2013-06-05 | 2013-08-26 | Novartis Ag | Influenza Virus Reassortierung |
BR112015030582A2 (pt) | 2013-06-06 | 2017-08-29 | Novartis Ag | Segmento de hemaglutinina da gripe quimérico e de neuraminidase quimérico, proteína de hemaglutinina quimérica, vírus da gripe rearranjado, métodos para preparação de um vírus da gripe rearranjado e para preparação de uma vacina e sistema de expressão |
JP2016524915A (ja) | 2013-07-15 | 2016-08-22 | ウィスコンシン アルムニ リサーチ ファンデイション | Mdck、ベロ細胞又は卵内で増強された複製を有する高力価の組換えインフルエンザウイルス |
RU2535153C1 (ru) * | 2013-09-04 | 2014-12-10 | Федеральное государственное унитарное предприятие "Санкт-Петербургский научно-исследовательский институт вакцин и сывороток и предприятие по производству бактерийных препаратов" Федерального медико-биологического агентства России (ФГУП СПбНИИВС ФМБА России) | Способ получения высокоочищенных вирионных концентратов |
ES2817928T3 (es) | 2013-11-15 | 2021-04-08 | Novartis Ag | Eliminación de impurezas de cultivos celulares residuales |
WO2015196150A2 (en) | 2014-06-20 | 2015-12-23 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
EP2966093A1 (en) | 2014-07-07 | 2016-01-13 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Process for the preparation of magnetic sulfated cellulose particles, magnetic sulfated cellulose particles and their use |
US10633422B2 (en) | 2015-06-01 | 2020-04-28 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA |
RU2614127C2 (ru) * | 2015-06-04 | 2017-03-22 | Общество с ограниченной ответственностью "НТфарма" | Способ получения концентрата рекомбинантных псевдоаденовирусных частиц, экспрессирующих ген гемагглютинина вируса гриппа A/California/07/2009(H1N1) |
JP2018524323A (ja) | 2015-06-26 | 2018-08-30 | セキラス ユーケー リミテッド | 抗原がマッチしたインフルエンザワクチン |
WO2017007839A1 (en) | 2015-07-06 | 2017-01-12 | Wisconsin Alumni Research Foundation (Warf) | Improved influenza virus replication for vaccine development |
US10416171B2 (en) | 2015-07-07 | 2019-09-17 | Seqirus UK Limited | Influenza potency assays |
CN109477074B (zh) | 2016-02-19 | 2023-01-24 | 威斯康星旧生研究基金会 | 用于疫苗开发的改进的乙型流感病毒复制 |
EP3601543A4 (en) | 2017-03-30 | 2021-01-27 | Merck Sharp & Dohme Corp. | ADDING NUCLEASES DIRECTLY TO CELL CULTURE TO FACILITATE DIGESTION AND RELEASE OF HOST CELL NUCLEIC ACIDS |
RU2670001C1 (ru) * | 2017-12-25 | 2018-10-17 | Федеральное государственное бюджетное учреждение науки Институт биохимии и физиологии растений и микроорганизмов Российской академии наук | Способ получения белков клеточной поверхности |
EP3737750B1 (en) | 2018-01-09 | 2024-06-05 | Theriva Biologics, Inc. | Alkaline phosphatase agents for treatment of neurodevelopmental disorders |
CA3094174A1 (en) | 2018-03-20 | 2019-09-26 | Synthetic Biologics, Inc. | Alkaline phosphatase agents for treatment of radiation disorders |
CA3094173A1 (en) | 2018-03-20 | 2019-09-26 | Synthetic Biologics, Inc. | Intestinal alkaline phosphatase formulations |
WO2020167432A2 (en) | 2019-01-23 | 2020-08-20 | Yoshihiro Kawaoka | Mutations that confer genetic stability to additional genes in influenza viruses |
CN113874496A (zh) | 2019-02-08 | 2021-12-31 | 威斯康星校友研究基金会(Warf) | 人源化细胞系 |
CN114929269A (zh) | 2019-05-01 | 2022-08-19 | 威斯康星校友研究基金会(Warf) | 用于疫苗开发的改进的流感病毒复制 |
WO2021041624A2 (en) | 2019-08-27 | 2021-03-04 | Yoshihiro Kawaoka | Recombinant influenza viruses with stabilized ha for replication in eggs |
MX2022006005A (es) | 2019-11-18 | 2022-10-27 | Seqirus Pty Ltd | Metodo para producir virus de la influenza reagrupados. |
KR102444684B1 (ko) * | 2020-04-29 | 2022-09-16 | 에스케이바이오사이언스(주) | 일회용 배양 공정 시스템을 이용한 인플루엔자 바이러스 생산 방법 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH589453A5 (zh) * | 1974-01-14 | 1977-07-15 | Sandoz Ag | |
US4500513A (en) * | 1979-05-15 | 1985-02-19 | Miles Laboratories, Inc. | Influenza vaccine production in liquid cell culture |
US4317811A (en) * | 1980-09-11 | 1982-03-02 | Merck & Co., Inc. | Herpes simplex type 1 subunit vaccine |
DE3237313A1 (de) * | 1982-10-08 | 1984-04-12 | Werner Heese | Verfahren zur gewinnung und reinigung antigenhaltiger loesungen, insbesondere fuer influenza-viren, aus antigenhaltiger allantoisfluessigkeit |
US4783411A (en) * | 1984-10-22 | 1988-11-08 | Janis Gabliks | Influenza-A virus vaccine from fish cell cultures |
US5173418A (en) * | 1985-05-10 | 1992-12-22 | Benzon Pharma, A/S | Production in Escherichia coli of extracellular Serratia spp. hydrolases |
US5006472A (en) * | 1988-06-03 | 1991-04-09 | Miles Inc. | Enzymatic purification process |
WO1990010058A2 (en) * | 1989-02-07 | 1990-09-07 | Bio-Technology General Corp. | Method for production and purification of hepatitis b vaccine |
EP0389925B1 (en) * | 1989-03-29 | 1995-12-27 | The Research Foundation Of State University Of New York | A method for purifying an outer membrane protein of Haemophilus influenzae |
DZ1706A1 (fr) * | 1992-08-07 | 2002-02-17 | Merck & Co Inc | Vaccin contre le virus de l'hepatite a. |
HRP950097A2 (en) * | 1994-03-08 | 1997-06-30 | Merck & Co Inc | Hepatitis a virus culture process |
ATE429246T1 (de) * | 1994-11-10 | 2009-05-15 | Baxter Healthcare Sa | Verfahren zur herstellung von biologischen produkten in protein-freiem kultur |
US5681746A (en) * | 1994-12-30 | 1997-10-28 | Chiron Viagene, Inc. | Retroviral delivery of full length factor VIII |
KR19990036028A (ko) * | 1995-08-01 | 1999-05-25 | 다니엘 케르니 | 일본뇌염 백신의 공업적인 생산방법 및 이에 의한 백신 |
KR19990063672A (ko) * | 1995-09-28 | 1999-07-26 | 유니버시티 오브 피츠버그 오브 더 코몬웰츠 시스템 오브 하이어 에듀케이션 | 표적배향된 미립자물 유전 면역화에 의한 세포-매개 면역응답의 자극. |
-
1998
- 1998-04-01 TW TW087104913A patent/TW570803B/zh not_active IP Right Cessation
- 1998-04-02 DE DE0870508T patent/DE870508T1/de active Pending
- 1998-04-02 TR TR1998/00613A patent/TR199800613A1/xx unknown
- 1998-04-02 ES ES98201056T patent/ES2129386T3/es not_active Expired - Lifetime
- 1998-04-02 DE DE69800383T patent/DE69800383T2/de not_active Expired - Lifetime
- 1998-04-02 EP EP98201056A patent/EP0870508B1/en not_active Revoked
- 1998-04-02 SI SI9830010T patent/SI0870508T1/xx unknown
- 1998-04-02 AT AT98201056T patent/ATE197406T1/de active
- 1998-04-02 DK DK98201056T patent/DK0870508T3/da active
- 1998-04-02 PT PT98201056T patent/PT870508E/pt unknown
- 1998-04-06 DZ DZ980072A patent/DZ2462A1/xx active
- 1998-04-06 PL PL98325722A patent/PL187982B1/pl unknown
- 1998-04-06 SK SK445-98A patent/SK282614B6/sk not_active IP Right Cessation
- 1998-04-06 NZ NZ330131A patent/NZ330131A/en not_active IP Right Cessation
- 1998-04-06 BR BR9801015-8A patent/BR9801015A/pt not_active Application Discontinuation
- 1998-04-06 CN CNB981080863A patent/CN1138564C/zh not_active Expired - Lifetime
- 1998-04-06 ID IDP980519A patent/ID20399A/id unknown
- 1998-04-06 NO NO981557A patent/NO323349B1/no not_active IP Right Cessation
- 1998-04-06 ZA ZA982915A patent/ZA982915B/xx unknown
- 1998-04-06 US US09/055,321 patent/US5948410A/en not_active Expired - Lifetime
- 1998-04-06 AU AU60659/98A patent/AU728939B2/en not_active Expired
- 1998-04-06 CA CA002234208A patent/CA2234208C/en not_active Expired - Lifetime
- 1998-04-06 HR HR980187A patent/HRP980187B1/xx not_active IP Right Cessation
- 1998-04-06 KR KR1019980012018A patent/KR100593235B1/ko not_active IP Right Cessation
- 1998-04-06 CZ CZ0105098A patent/CZ297492B6/cs unknown
- 1998-04-06 RU RU98106860/13A patent/RU2197264C2/ru active
- 1998-04-06 IL IL12396198A patent/IL123961A/xx not_active IP Right Cessation
- 1998-04-06 HU HU9800802A patent/HUP9800802A3/hu not_active Application Discontinuation
- 1998-04-07 JP JP11010198A patent/JP5258127B2/ja not_active Expired - Lifetime
- 1998-04-08 AR ARP980101611A patent/AR011216A1/es not_active Application Discontinuation
- 1998-04-08 UA UA98041787A patent/UA42089C2/uk unknown
- 1998-11-17 HK HK98112068A patent/HK1010833A1/xx not_active IP Right Cessation
-
1999
- 1999-01-01 GR GR990300017T patent/GR990300017T1/el unknown
-
2000
- 2000-11-09 GR GR20000402476T patent/GR3034798T3/el not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW570803B (en) | Influenza vaccine | |
KR101153929B1 (ko) | 기능성 인플루엔자 바이러스 유사입자 | |
Heggeness et al. | Conformation of the helical nucleocapsids of paramyxoviruses and vesicular stomatitis virus: reversible coiling and uncoiling induced by changes in salt concentration. | |
DE69534449T2 (de) | Vektor und methode zur herstellung von influenza hämagglutinin | |
CN101715487A (zh) | 血凝素多肽中有变化的b型流感病毒 | |
EA014062B1 (ru) | Вирусные вакцины, полученные из клеток с низкими уровнями остаточной клеточной днк | |
EP1982727A1 (en) | Method for purification of viral proteins | |
JP2000507448A (ja) | インフルエンザウイルスの複製のための動物細胞および方法 | |
CN103540568A (zh) | 制备流感病毒的多质粒系统 | |
US20020197705A1 (en) | Methods to identify mutant cells with altered sialic acid | |
Matumoto | Multiplication of measles virus in cell cultures | |
JPH04502410A (ja) | ウイルスの生産およびワクチン使用のためのウイルスエンベロープタンパク質の精製 | |
US4327182A (en) | Purification of influenza sub-unit vaccine | |
EP3234113B1 (en) | A method for a large scale virus purification | |
EP2364167B1 (en) | Method for production of ph stable enveloped viruses | |
CN116162601A (zh) | 一种流感病毒裂解疫苗的制备方法 | |
CN102600468A (zh) | 一种含mf59佐剂禽流感病毒裂解疫苗的制备工艺 | |
CN107164334B (zh) | 一种猪圆环病毒繁殖培养基及其应用 | |
MXPA98002766A (en) | Vaccine against influe | |
CN117603922A (zh) | 一种流感病毒裂解液、流感病毒抗原及其制备方法与应用 | |
DE69535716T2 (de) | Methode für die Produktion von multivalenten Influenza Hämagglutinin Vakzinen | |
Breuning et al. | Characterization of a cold-sensitive (cs) recombinant between two influenza A strains | |
Davis | Neuraminidase of influenza A virus: studies on immunogenicity and interaction with other viral proteins and lipid | |
Corbitt | Studies on the Replication of the Respiratory Syncytial Virus | |
JPH10316583A (ja) | 抗インフルエンザウイルス剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GD4A | Issue of patent certificate for granted invention patent | ||
MM4A | Annulment or lapse of patent due to non-payment of fees |